What Purposeful does

Purposeful is a privately held biotech company headquartered in Athens, Greece, founded in 2018, that uses an AI-powered drug repurposing engine to identify new therapeutic uses for already-marketed drugs, with a strategic focus on rare genetic and neurological diseases. The company's core technology is an AI Drug ReDiscovery Engine that integrates omics data and chemistry-related data to predict novel mechanism-of-action and target opportunities for existing compounds, combined with a Model-Informed Drug Discovery and Development (MID3) framework that guides preclinical-to-clinical translation. Purposeful applies this engine to a pipeline of more than 20 candidates spanning seven therapeutic areas, including a clinical-stage lead asset combining Ergoloid Mesylates and 5-Hydroxytryptophan in Fragile X Syndrome (NCT05030129 at Rush University Medical Center, with EMA Orphan Designation EU/3/22/2586), plus preclinical programs in Pitt-Hopkins Syndrome, Glioblastoma, Psoriasis, SYNGAP1-related intellectual disability, Duchenne Muscular Dystrophy, Huntington's disease, and Acrodysostosis.

The company's revenue model is centered on pharmaceutical development and licensing, generating future income through licensing deals, co-development partnerships, and eventual product commercialization for rare disease treatments; to date no commercial revenue has been disclosed and the company has been funded primarily via a $200,000 seed round from Metavallon VC in October 2018. Purposeful serves three primary customer segments: rare disease patients and families, patient advocacy organizations such as FRAXA Research Foundation and Pitt Hopkins Research Foundation, and pharmaceutical partners such as Leo Pharma Ltd. Its go-to-market is sales-led and partnership-driven rather than direct product distribution, with collaborations spanning patient advocacy groups (FRAXA, FRAXA-DVI, PHRF), pharmaceutical companies (Leo Pharma, BIOEMTECH), academic medical centers (Rush University Medical Center, University of Athens), and conference-led awareness (Gordon Research Conference, Findacure, International Conference on Rare Diseases).

Name

Purposeful

Legal name

Purposeful

Website

https://purposeful.eu

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

Purposeful is an Athens-based biotech that uses an AI drug repurposing engine to discover new treatments for rare diseases by identifying alternative effects of already-marketed drugs, partnering with patient foundations and pharmaceutical companies such as FRAXA and Leo Pharma.

Ownership category

akta.pro rank

Product category

AI-Driven Drug Repurposing / Rare Disease Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

akta.pro secondary industries

Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA), Genetic & Genomic Rare Disease Therapeutics (HLAIAIAA), Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)

Keywords

• Drug repurposing platform
• AI drug discovery
• Rare disease therapeutics
• Computational biology
• Pharmaceutical pipeline development

Headquarters

HQ city

Athens

HQ country

Greece

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Development & Licensing: Developing pharmaceutical products through to market authorization, generating revenue through licensing deals, co-development partnerships, and eventual product commercialization for rare disease treatments.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

Purposeful develops pharmaceutical products for rare diseases by repurposing already-marketed drugs through its AI-powered computational engine. The company combines machine learning, big data analytics, and Model-Informed Drug Discovery and Development (MID3) to identify novel therapeutic uses for existing compounds, then advances candidates through preclinical validation and clinical trials via partnerships with pharmaceutical companies, academic institutions, and patient advocacy groups.

Product overview

Purposeful is a biotech company offering AI-powered drug repurposing services for rare diseases. Their core product is an AI Drug ReDiscovery Engine that identifies new therapeutic uses for already marketed drugs. The company maintains a pipeline of drug candidates including treatments for Fragile X Syndrome (in clinical trial), Pitt-Hopkins Syndrome, Glioblastoma, Psoriasis, SYNGAP1-related intellectual disability, Duchenne Muscular Dystrophy, Huntington's disease, and Acrodysostosis. Purposeful combines AI computational analysis with expert opinion and Model Informed Drug Discovery and Development (MID3) approaches to advance candidates from discovery through preclinical validation toward clinical trials and market authorization.

Differentiator

Problem solved

Functional benefit

Products and services

• AI Drug ReDiscovery Engine Purposeful's core computational platform that uses AI and machine learning to identify drug repurposing candidates for rare diseases by predicting additional effects of existing marketed drugs; built on big data analytics combining omics and chemo-related data with expert validation.
• Fragile X Syndrome Treatment (Ergoloid Mesylates + 5-HTP) Drug repurposing candidate combining Ergoloid Mesylates and 5-Hydroxytryptophan for the treatment of Fragile X Syndrome, acting via CNS targets (adrenergic, dopaminergic, serotonergic receptors) and increased serotonin production; in proof-of-concept clinical trial at Rush University Medical Center and recipient of EU orphan medicinal product designation.
• Pitt-Hopkins Syndrome Drug Candidate Repurposed drug candidate for Pitt-Hopkins Syndrome (PTHS), an ultra-rare neurodevelopmental disorder; has completed successful preclinical studies including dose-ranging, showing a safe and potent profile, with further investigation underway in collaboration with the Pitt Hopkins Research Foundation.
• Glioblastoma Drug Candidate Drug repurposing candidate for Glioblastoma (GBM) developed in partnership with BIOEMTECH; following successful preclinical in-vivo results, new experiments for an alternative dosing strategy are scheduled, and a patent application has been filed.
• Psoriasis Drug Candidate Drug candidate for psoriasis developed via Purposeful's open innovation partnership with LEO Pharma; successful in-vitro preclinical results supported two patent applications, and in-vivo testing is planned in collaboration with the School of Pharmacology, University of Athens.
• SYNGAP1-Related Intellectual Disability Drug Candidate Drug repurposing candidate for SYNGAP1-related intellectual disability, a genetic disorder impacting brain function and development associated with moderate to severe intellectual disability, epilepsy, and developmental delays; ~50% of patients also have an autism diagnosis.

Quantifiable outcome

• Development timelines reduced through drug repurposing approach
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature3 records

Partnerships

Six partnerships are on record, tiered core, major and supporting.

• FRAXA Research Foundation & FRAXA-DVIcoreStrategic or Co-development Partner · 1 January 2021Purposeful partners with FRAXA and FRAXA-DVI to identify drug repurposing candidates against Fragile X Syndrome. This collaboration has led to Purposeful's first clinical trial. FRAXA has funded more than $30 million in biomedical research and three Nobel Laureates sit on their Scientific Advisory Board.
• BIOEMTECHcoreStrategic or Co-development PartnerPurposeful partners with BIOEMTECH (also referred to as Biomtech) to identify drug repurposing candidates against Glioblastoma. A series of in-vivo experiments were successfully completed and next steps are being planned. BIOEMTECH is a pioneer in molecular imaging technology for pre-clinical research.
• Leo Pharma LtdmajorStrategic or Co-development PartnerPurposeful collaborated with Leo Pharma Ltd via its Open Innovation program to discover and validate drugs to treat Inflammatory and Dermatology indications. LEO Pharma A/S is a global leader in medical dermatology.
• Pitt Hopkins Research Foundation (PHRF)coreStrategic or Co-development PartnerCollaboration with Pitt Hopkins Research Foundation announced in April 2022 to advance research into Pitt-Hopkins Syndrome treatments.
• Rush University Medical CentercoreStrategic or Co-development PartnerClinical trial site conducting proof-of-concept trial for Fragile X Syndrome treatment using Ergoloid Mesylates and 5-Hydroxytryptophan combination (ClinicalTrials.gov NCT05030129). First results anticipated after trial completion.
• School of Pharmacology, University of AthenssupportingStrategic or Co-development PartnerCollaboration for in-vivo testing of psoriasis treatment candidates following successful in vitro preclinical results.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• BenevolentAI: Established AI-driven drug discovery company applying machine learning to identify novel therapeutics across multiple disease areas, including rare diseases. Compares to Purposeful on AI-driven target identification and drug repurposing methodology, though at much greater scale and capital.
• Exscientia: AI-driven drug design and development company combining machine learning with automated experimentation. Comparable on AI-driven small-molecule discovery methodology, though focused on novel drug design rather than repurposing and operating at much larger scale.
• Insilico Medicine: AI drug discovery platform covering both novel target identification and drug repurposing across multiple therapeutic areas. Compares on AI-platform architecture and target-discovery methodology, though operates at substantially larger scale with broader pipeline.
• Recursion Pharmaceuticals: AI-driven drug discovery company using machine learning and high-throughput biology to identify novel therapeutics. Compares on AI-driven discovery approach, though at vastly larger scale and with broader therapeutic focus than Purposeful's rare-disease specialization.

Emerging players

• Lantern Pharma: AI-driven precision oncology company using machine learning to identify and develop drug combinations including repurposed compounds. Comparable on AI-repurposing methodology and clinical-stage pipeline, though focused on oncology rather than rare genetic diseases.
• Aria Pharmaceuticals: AI-driven drug discovery and repurposing company focused on identifying new therapeutic applications for existing compounds. Compares on computational drug repurposing methodology and early-stage pipeline development.

Direct peers

• Healx: Cambridge-based AI-driven drug repurposing company focused specifically on rare diseases, including Fragile X and other neurodevelopmental disorders. Most directly comparable peer in terms of AI-repurposing platform, rare disease focus, and early-stage clinical pipeline.
• Biovista: Drug repurposing company using computational methods to identify new indications for existing drugs. Closely comparable business model — AI/computational repurposing platform targeting both rare and common diseases.
• Pharnext: French clinical-stage biopharmaceutical company specializing in drug repositioning and combination therapy development for rare neurological diseases. Comparable on repurposing + combination therapy approach in rare neurology and on early clinical-stage status.

Others

• Cyclica: AI-driven polypharmacology and drug repurposing platform (now part of Recursion). Comparable on computational drug repurposing and AI-platform technology, though primarily provides technology platform services rather than developing its own pipeline.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xtwitter.com/PurposefulDR
• LinkedInlinkedin.com/company/purposeful-eu

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Purposeful